Gilead Sciences, Inc.

GILD • Drug Manufacturers - General

$151.00

▼ -0.22 (-0.15%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$187.69B

Crecimiento

27.9%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 28.9%Flujo de caja libre positivo · 7.6Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 17.94Liquidez saludable · 1.68

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 12:07 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$151.00

Change-0.15%

Shares Out1.24B

Market Cap$187.69B

Enterprise Value$184.51B

52W Range108.46 - 157.29

Beta0.34

P/E-57.93

P/S6.16

P/B15.98

P/FCF14.22

EV/Sales6.06

Price$151.00

Change-0.15%

Shares Out1.24B

Market Cap$187.69B

Enterprise Value$184.51B

52W Range108.46 - 157.29

Beta0.34

P/E-57.93

P/S6.16

P/B15.98

P/FCF14.22

EV/Sales6.06

EV/EBITDA-3,481.28

EV/FCF13.98

Earnings Yield-1.73%

FCF Yield7.03%

Dividend Yield2.17%

Gross Margin78.83%

Oper. Margin39.74%

Profit Margin28.90%

Debt/Eq1.09

Current Ratio1.68

Quick Ratio1.31

Revenue 5Y27.93%

Target$151.25

Target Upside0.17%

Target Median$152.50

Target Range123.00 - 180.00

Volume8.22M

Avg Volume7.47M

EPS Surprise0.12

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

90/100

Fortaleza financiera

Deuda, caja, estabilidad

81/100

Potencial de crecimiento

Ingresos y expansión

31/100

Atractivo del precio

Barata o cara hoy

66/100

Por qué este puntaje▼

Márgenes estables o en mejora · 28.9%Flujo de caja libre positivo · 7.6Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 17.94Liquidez saludable · 1.68Tendencia de crecimiento negativa

Analyst view

Analyst sentiment and price target

GILD

Analyst sentiment

Based on 58 analyst votes · 2026-09-05

83/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$123.00

Promedio

$158.44

Mediana

$162.50

Alto

$180.00

Resumen de la compañía

IPO: 1/22/1992

Industria: Drug Manufacturers - General

P/B i: 15.98

Deuda / Patrimonio i: 1.09

Margen operativo: 39.74%

Margen neto: 28.90%

ROE i: -

ROIC: -

Salud financiera

Puntaje16 / 20

Deuda / Patrimonio: 1.09

Ratio corriente: 1.68

Ratio rápido: 1.31

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

O'Day Daniel Patrick

Transacción: 08/03/2026

VENTA

Cambio

-600

Precio

$131.34

Presentación

08/04/2026

Tipo

VENTA

Mercier Johanna

Transacción: 07/15/2026

VENTA

Cambio

-3,000

Precio

$129.92

Presentación

07/16/2026

Tipo

VENTA

Dickinson Andrew D

Transacción: 07/15/2026

VENTA

Cambio

-3,000

Precio

$129.93

Presentación

07/16/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
O'Day Daniel Patrick	VENTA	-600	$131.34	08/03/2026	08/04/2026
Mercier Johanna	VENTA	-3,000	$129.92	07/15/2026	07/16/2026
Dickinson Andrew D	VENTA	-3,000	$129.93	07/15/2026	07/16/2026
O'Day Daniel Patrick	VENTA	-3,100	$127.08	07/01/2026	07/02/2026
Dickinson Andrew D	VENTA	-3,000	$125.40	06/15/2026	06/16/2026
Mercier Johanna	VENTA	-450	$125.40	06/15/2026	06/16/2026
O'Day Daniel Patrick	VENTA	-8,779	Not reported	06/10/2026	06/11/2026
O'Day Daniel Patrick	VENTA	-4,213	$121.48	06/10/2026	06/11/2026
Mercier Johanna	VENTA	-2,796	Not reported	06/10/2026	06/11/2026
Mercier Johanna	VENTA	-1,341	$121.48	06/10/2026	06/11/2026
Dickinson Andrew D	VENTA	-2,796	Not reported	06/10/2026	06/11/2026
Dickinson Andrew D	VENTA	-1,341	$121.48	06/10/2026	06/11/2026
Cain Wettan Keeley M	VENTA	-283	$121.48	06/10/2026	06/11/2026
Cain Wettan Keeley M	VENTA	-589	Not reported	06/10/2026	06/11/2026
Berger Dietmar	VENTA	-263	$121.48	06/10/2026	06/11/2026
Berger Dietmar	VENTA	-533	Not reported	06/10/2026	06/11/2026
O'Day Daniel Patrick	VENTA	-1,038	$132.97	06/01/2026	06/02/2026
Mercier Johanna	VENTA	-25,000	$66.64	05/15/2026	05/18/2026
Mercier Johanna	VENTA	-700	$132.75	05/15/2026	05/18/2026
Dickinson Andrew D	VENTA	-3,000	$132.27	05/15/2026	05/18/2026

Sobre la compañía

Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Fuente - Link

Competidores

AMGN BMY BSX DHR GSK MRK NVO PFE SNY SYK

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.

24/7 Wall Street

Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research

Can Bixlenvo Unlock New Growth for Gilead's HIV Business?

GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.

Zacks Investment Research

Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?

Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research

Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	1.91	2.03	0.12
2026-02-10	1.81	1.86	0.05
2025-10-30	2.13	2.47	0.34
2025-08-07	1.96	2.01	0.05
2025-04-24	1.78	1.81	0.03
2025-02-11	1.74	1.9	0.16
2024-11-06	1.53	2.02	0.49
2024-08-08	1.61	2.01	0.4
2024-04-25	-1.49	-1.32	0.17
2024-02-06	1.76	1.72	-0.04
2023-11-07	1.91	2.29	0.38
2023-08-03	1.6	1.34	-0.26